Eurofins Cerep SAS (ALECR)
XPAR XPAR Primary Summary
Eurofins Cerep SAS (ALECR) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Eurofins Cerep SAS ever had a stock split?
Eurofins Cerep SAS Profile
| Professional Services Industry | Industrials Sector | Mr. Damien Vielliard CEO | XPAR Exchange | FR0013256518 ISIN |
| France Country | - Employees | - Last Dividend | 27 Jul 2017 Last Split | - IPO Date |
Overview
Eurofins-Cerep SA is a specialized company providing comprehensive drug discovery services to various segments of the healthcare industry, including pharmaceutical, biopharmaceutical, and biotechnology companies both in France and on an international scale. Initially established as Cerep SA in 1989, the company underwent a name change to Eurofins-Cerep SA in June 2014, signifying a major milestone in its development. With its headquarters located in Celle-Lévescault, France, Eurofins-Cerep has carved a niche for itself in the drug discovery services industry by leveraging its extensive expertise and cutting-edge research methodologies. As a strategic move to bolster its footing in the industry, Eurofins-Cerep SA operates as a key subsidiary of Eurofins Discovery Services LUX Holding SARL, further enhancing its capabilities and service offerings to clientele across the globe.
Products and Services
Eurofins-Cerep SA distinguishes itself in the pharmaceutical and biotechnology sectors by offering a diversified portfolio of research services aimed at facilitating the drug discovery process. The highlights of their service offerings include:
- Compound Management: This service provides a comprehensive solution for the storage, management, and retrieval of chemical compounds. By employing systematic approaches and leveraging cutting-edge technology, Eurofins-Cerep ensures efficient compound management that aids in streamlining the drug discovery process.
- High-throughput Screening and Profiling: Eurofins-Cerep SA utilizes high-throughput screening (HTS) techniques to rapidly evaluate the potential of large numbers of chemical compounds. This technique is instrumental in identifying candidates for further research and development. Additionally, the company offers profiling services to assess the pharmacological properties of these compounds, thereby providing valuable insights into their efficacy and safety profiles. This combination of high-throughput screening and detailed profiling is essential for accelerating the drug development pipeline.
Contact Information
